Carregant...

Rituximab in the treatment of non-Hodgkin’s lymphoma

Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL). Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hauptrock, Beate, Hess, Georg
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727901/
https://ncbi.nlm.nih.gov/pubmed/19707443
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!